Elucidation of the mechanism underlying the UCA1-miR-495-HGF/c-MET regulatory network involved in cetuximab resistance will lead to the development of novel agents and therapeutic approaches for CRC in the future. This evidence concerns the gene UCA1 and colorectal carcinoma.